Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

kelly smith

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Boosting innovation in healthcare and scientific communications

It’s time for communications to be brave and bring the outside in

My Dad was ‘one in a million’​, as the saying goes. But actually he was one in 300 million (of patients worldwide with rare disease)

Emily Wigginton, Client Services Director, OPEN Health Patient & Brand Communications

OPEN Health

- PMLiVE

GSK seeks EU approval for Trelegy in adult asthma patients

If approved would open up a large market for the triple therapy

- PMLiVE

Case-study for thalassaemia: Dimitri Azzopardi

An in-depth look at beta thalassaemia for Rare Disease Day

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

Delivering change through better rare disease communications

OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes.

OPEN Health

- PMLiVE

No patient left behind

How healthcare comms helps create rare disease communities

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links